rifamycin-sv and HIV-Infections

rifamycin-sv has been researched along with HIV-Infections* in 2 studies

Other Studies

2 other study(ies) available for rifamycin-sv and HIV-Infections

Article	Year
No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients. AIDS (London, England), 2013, Jan-28, Volume: 27, Issue:3 Rifabutin has been substituted for rifampicin when treating tuberculosis (TB)/HIV coinfection. However, despite reports of anti-TB treatment failure and acquired rifamycin resistance, long-term clinical outcome data are lacking. Observational analyses performed in a UK TB/HIV cohort demonstrated no difference in severe adverse events, anti-TB treatment completion, relapse frequency or subsequent rifamycin resistance when rifampicin and rifabutin were compared, using different combinations of antiretroviral therapy. Our data support the wider use of rifabutin in TB/HIV coinfection. Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Coinfection; Drug Resistance, Bacterial; Female; HIV Infections; Humans; Male; Retrospective Studies; Rifabutin; Rifamycins; Treatment Outcome; Tuberculosis, Pulmonary	2013
Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Mar-01, Volume: 38, Issue:5 We sought to determine the risk of acquired rifamycin resistant (ARR) tuberculosis associated with rifampin- versus rifabutin-based directly observed therapy and to assess the risk factors for relapse of tuberculosis. This observational cohort study included patients with culture-confirmed rifamycin-susceptible tuberculosis reported to the Baltimore City Health Department (Baltimore, MD) during the period of January 1993 through December 2001. Of the 407 patients, 108 (27%) were human immunodeficiency virus (HIV) seropositive, 161 (40%) were HIV seronegative, and 138 (34%) had an unknown serostatus. Three (2.8%) of 108 HIV-seropositive persons had ARR tuberculosis, compared with 0 of 299 persons with negative or unknown HIV serostatus (P=.02). Among HIV-seropositive patients, 3 (3.7%) of 81 who were treated with rifampin and 0 of 27 who were treated with rifabutin had ARR tuberculosis (P=.57). Among HIV-seropositive patients, the only risk factor for recurrent tuberculosis was a low median initial CD4+ T lymphocyte count (51 vs. 138 cells/mm3; P=.02). The median CD4+ T lymphocyte count among patients with ARR tuberculosis was 51 cells/mm3. ARR tuberculosis can occur with rifampin-based regimens, but in this study, the risk was not significantly higher than that for a rifabutin-based regimen. Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Female; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Male; Middle Aged; Recurrence; Rifabutin; Rifamycins; Risk Factors; Serologic Tests; Tuberculosis	2004

Article

Year

No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients.

AIDS (London, England), 2013, Jan-28, Volume: 27, Issue:3

Rifabutin has been substituted for rifampicin when treating tuberculosis (TB)/HIV coinfection. However, despite reports of anti-TB treatment failure and acquired rifamycin resistance, long-term clinical outcome data are lacking. Observational analyses performed in a UK TB/HIV cohort demonstrated no difference in severe adverse events, anti-TB treatment completion, relapse frequency or subsequent rifamycin resistance when rifampicin and rifabutin were compared, using different combinations of antiretroviral therapy. Our data support the wider use of rifabutin in TB/HIV coinfection.

Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Coinfection; Drug Resistance, Bacterial; Female; HIV Infections; Humans; Male; Retrospective Studies; Rifabutin; Rifamycins; Treatment Outcome; Tuberculosis, Pulmonary

2013

Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Mar-01, Volume: 38, Issue:5

We sought to determine the risk of acquired rifamycin resistant (ARR) tuberculosis associated with rifampin- versus rifabutin-based directly observed therapy and to assess the risk factors for relapse of tuberculosis. This observational cohort study included patients with culture-confirmed rifamycin-susceptible tuberculosis reported to the Baltimore City Health Department (Baltimore, MD) during the period of January 1993 through December 2001. Of the 407 patients, 108 (27%) were human immunodeficiency virus (HIV) seropositive, 161 (40%) were HIV seronegative, and 138 (34%) had an unknown serostatus. Three (2.8%) of 108 HIV-seropositive persons had ARR tuberculosis, compared with 0 of 299 persons with negative or unknown HIV serostatus (P=.02). Among HIV-seropositive patients, 3 (3.7%) of 81 who were treated with rifampin and 0 of 27 who were treated with rifabutin had ARR tuberculosis (P=.57). Among HIV-seropositive patients, the only risk factor for recurrent tuberculosis was a low median initial CD4+ T lymphocyte count (51 vs. 138 cells/mm3; P=.02). The median CD4+ T lymphocyte count among patients with ARR tuberculosis was 51 cells/mm3. ARR tuberculosis can occur with rifampin-based regimens, but in this study, the risk was not significantly higher than that for a rifabutin-based regimen.

Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Female; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Male; Middle Aged; Recurrence; Rifabutin; Rifamycins; Risk Factors; Serologic Tests; Tuberculosis

2004